263 related articles for article (PubMed ID: 19642140)
21. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
22. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
23. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
26. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
27. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
28. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
30. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
[TBL] [Abstract][Full Text] [Related]
31. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
32. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
33. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
34. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
[TBL] [Abstract][Full Text] [Related]
35. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
36. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
37. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
38. Loss of MAL expression in precancerous lesions of the esophagus.
Mimori K; Nishida K; Nakamura Y; Ieta K; Yoshikawa Y; Sasaki A; Ishii H; Alonso MA; Mori M
Ann Surg Oncol; 2007 May; 14(5):1670-7. PubMed ID: 17151798
[TBL] [Abstract][Full Text] [Related]
39. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
Leong CT; Ong CK; Tay SK; Huynh H
Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
[TBL] [Abstract][Full Text] [Related]
40. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
Kang S; Dong SM; Park NH
Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]